Natco Pharma jumps 3.3% to ₹840 after the court lets generic risdiplam launch immediately with a discount.

• The court dismissed Roche's appeal, clearing the path for Natco's generic risdiplam in India at ₹15,900.
• Natco will offer discounts through the patient access programme for deserving patients to ensure broader availability.
• Trading volume surged to 2.2 million shares, over five times the 30‑day average in today's session.